Amgen Inc (AMGN)

186.32
NASDAQ : Health Care
Prev Close 186.32
Day Low/High 0.00 / 0.00
52 Wk Low/High 133.64 / 191.10
Avg Volume 2.48M
Exchange NASDAQ
Shares Outstanding 729.67M
Market Cap 136.06B
EPS 10.30
P/E Ratio 16.98
Div & Yield 4.60 (2.50%)

Latest News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Data Supports Safety and Efficacy of Repatha in Patients With Diabetes

FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer

FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer

Approval Based on Totality of Evidence From Global Development Program Showing MVASI™ is Highly Similar to Avastin® (bevacizumab)

Amgen Builds on a Breakout

Amgen Builds on a Breakout

We would suggest doing some buying here.

EVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine

EVENITY™ (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine

EVENITY Followed by Alendronate Reduced the Incidence of New Vertebral, Clinical, Non-Vertebral and Hip Fractures Compared to Alendronate Alone

Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress

Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress

Study Between ABP 980 and Trastuzumab in Patients With HER2-Positive Early Breast Cancer Adds to the Totality of Evidence of Biosimilarity

Amgen Highlights The Latest EVENITY™ (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting

Amgen Highlights The Latest EVENITY™ (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting

First Presentation of Detailed EVENITY ARCH Study Results and FRAME Extension Final Analysis

New Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies

New Data Demonstrate Aimovig™ (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies

Aimovig Reduced Monthly Migraine Days for Patients With Chronic Migraine and Prior Treatment Failure, a Population With Significant Unmet Need

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I've Prepared for Hurricane Irma -- and a Market Pullback

As a Miami resident, I've learned the value of hurricane preparation and the 'Jensen Rules'.

How I'm Prepared for Irma -- and a Pullback

How I'm Prepared for Irma -- and a Pullback

As a Florida resident, I've learned the value of preparation and the 'Jensen Rules'.

Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma

Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma

Novel Investigational Drug is Designed to Block Thymic Stromal Lymphopoietin (TSLP) - An Upstream Driver of Inflammation in Asthma

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Today's breakout move in the stock is a highlight of the surging sector.

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Today's breakout move in the stock is a highlight of the surging sector.

New Virtual Histology Sub-Study Evaluates Impact Of Repatha® (Evolocumab) On Coronary Artery Plaque Composition

New Virtual Histology Sub-Study Evaluates Impact Of Repatha® (Evolocumab) On Coronary Artery Plaque Composition

Late-Breaking Clinical Trial Presented at ESC 2017

New Repatha® (evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels

New Repatha® (evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels

Data Supports Lower LDL-C Levels for High-Risk Cardiovascular Patients

Amgen Becomes #44 Most Shorted Nasdaq 100 Component, Replacing Check Point Software Technologies

Amgen Becomes #44 Most Shorted Nasdaq 100 Component, Replacing Check Point Software Technologies

The most recent short interest data has been released for the 08/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Amgen Foundation Expands The Amgen Biotech Experience, Bringing Total Program Reach To 900,000 High School Students By 2020

Amgen Foundation Expands The Amgen Biotech Experience, Bringing Total Program Reach To 900,000 High School Students By 2020

Program to Expand to Australia, Canada, China, France, Germany, Hong Kong SAR, Italy, Netherlands, and Singapore

Overall Survival Analysis From KYPROLIS® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology

Overall Survival Analysis From KYPROLIS® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology

KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent Compared to Velcade® (bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

New Economic Analysis Based On Repatha® (Evolocumab) Outcomes Data Published In JAMA Cardiology

New Economic Analysis Based On Repatha® (Evolocumab) Outcomes Data Published In JAMA Cardiology

Repatha Used in Patients at High-Risk For Cardiovascular Events is Cost-Effective at Net Prices at or Below $9,669

Amgen To Present New Data From The Repatha® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017

Amgen To Present New Data From The Repatha® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017

Analysis Evaluates the Effect of Repatha in More Than 5,000 Patients With a History of Stroke

Amgen And Humana Partner For Improved Health Outcomes And Efficiency

Amgen And Humana Partner For Improved Health Outcomes And Efficiency

Partnership to Target Multiple Serious Diseases Using Real World Data Studies

Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine

Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine

Study Showed Lowering LDL-C With Repatha Did Not Impair Cognition

Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration

Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration

Filing for ABP 980, a Biosimilar Candidate to Herceptin® (trastuzumab), Supported by Phase 3 Data in Patients With HER2-Positive Early Breast Cancer

TheStreet Quant Rating: A+ (Buy)